NASDAQ:IMMX Immix Biopharma Q4 2024 Earnings Report $2.06 -0.04 (-1.90%) Closing price 04:00 PM EasternExtended Trading$2.06 0.00 (0.00%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Immix Biopharma EPS ResultsActual EPS-$0.16Consensus EPS -$0.25Beat/MissBeat by +$0.09One Year Ago EPSN/AImmix Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmix Biopharma Announcement DetailsQuarterQ4 2024Date3/24/2025TimeAfter Market ClosesConference Call DateTuesday, March 25, 2025Conference Call Time8:00AM ETUpcoming EarningsImmix Biopharma's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Monday, November 10, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Immix Biopharma Earnings HeadlinesImmix Biopharma, Inc. to Host Investor Meetings at 37th Annual Piper Sandler Healthcare ConferenceOctober 1 at 9:11 AM | quiverquant.comQImmix Biopharma to Present at the 37th Annual Piper Sandler Healthcare ConferenceOctober 1 at 8:45 AM | globenewswire.comBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positioned at the absolute center of this incoming capital flood— a project so fundamentally essential to the crypto ecosystem that institutional investors simply cannot ignore it.October 3 at 2:00 AM | Crypto 101 Media (Ad)Immix Biopharma, Inc.: Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2September 19, 2025 | finanznachrichten.deImmix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2September 18, 2025 | globenewswire.comImmix Biopharma price target raised to $8 from $7 at H.C. WainwrightSeptember 12, 2025 | msn.comSee More Immix Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immix Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immix Biopharma and other key companies, straight to your email. Email Address About Immix BiopharmaImmix Biopharma (NASDAQ:IMMX) (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy. The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment. IMX-110 is currently being evaluated in early-phase clinical trials, with initial data assessing safety, tolerability and preliminary signs of clinical benefit. In addition to its flagship program, Immix Biopharma is advancing a pipeline of next-generation myeloid modulators in preclinical development, seeking to expand application across multiple tumor types. Headquartered in the United States, Immix Biopharma operates research and development facilities dedicated to advancing its immuno-oncology platform through early clinical stages. The management team brings together seasoned professionals in oncology drug development and translational research, supported by collaborations with leading academic and clinical institutions. With a commitment to addressing unmet needs in cancer care, Immix Biopharma is positioned to translate innovative science into potential new therapies for patients worldwide.View Immix Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.